On the contrary, the combination of the other anti-CTLA-4 mAb ID1 with Nivolumab, PD-1_1 or PD-L1_1, even though equally or more effective on tumor cells than the combination of Ipilimumab and Nivolumab, showed much lower toxicity for HFC, as highlighted by reduced LDH release (Figure 6C) and lower levels of secreted pro-inflammatory IL-6. The gene discussed is CTLA4; the disease is neoplasm.